Edesa Biotech, Inc. — Director's Dealing 2015

Jun 15, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stellar Biotechnologies, Inc. (SBOTF)
CIK: 0001540159
Period of Report: 2015-06-10

Reporting Person: MORSE DANIEL E. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-06-10	Stock Option (Right to Buy)	$.72	A	25000	Acquired	2022-06-10	Common Shares (25000)	Direct

Footnotes

F1: The options are exercisable at a price of C$0.89. The U.S. dollar price reported on this Form 4 in column 2 reflects the U.S. dollar equivalent exercise price on the date of grant, calculated at the closing price for cable transfers in Canadian dollars as reported by Bloomberg on such date of U.S. $1.00=CDN$1.23

F2: One-third of the option vested immediately, one-third of the option vests on the first anniversary of June 10, 2015, and one-third vests 18 months after June 10, 2015.